Blocking versus cytotoxic antibody in HL-A- and mixed lymphocyte culture-identical and nonidentical human renal transplant recipients.
Blocking antibody directed against donor responding cells has been found to develop in HL-A-mixed lymphocyte culture-identical donor-recipient combinations after renal transplantation in which splenectomy was not performed. Cytotoxic antibody associated with rejection episodes and detected only by the discriminatory mixed lymphocyte culture developed in other HL-A-mixed lymphocyte culture-identical combinations as well. It disappeared as blocking antibody appeared and the post-transplant course became uneventful. In addition, both cytotoxic and blocking activity were shown to develop and coexist in a patient who received two successive renal transplants: cytotoxic against donor 1 (kidney rejected), and blocking against donor 2 (kidney accepted). These findings are taken to be strong evidence in favor of qualitatively demonstrable separate antibody molecules dealing with two separate functions, i.e., cytotoxicity versus enhancement or immunoregulation.
D000818:Animals; D000917:Antibody Formation; D000961:Antilymphocyte Serum; D001379:Azathioprine / Q000627:therapeutic use; D001667:Binding, Competitive; D003601:Cytotoxicity Tests, Immunologic; D006649:Histocompatibility Antigens; D006736:Horses / Q000276:immunology; D006801:Humans; D007111:Immunity, Cellular; D007165:Immunosuppression Therapy; D016030:Kidney Transplantation; D007959:Lymphocyte Culture Test, Mixed; D008775:Methylprednisolone / Q000627:therapeutic use; D013154:Spleen / Q000276:immunology; D013156:Splenectomy; D014184:Transplantation, Homologous
D000961:Antilymphocyte Serum; D006649:Histocompatibility Antigens; D001379:Azathioprine; D008775:Methylprednisolone